Melanotan 2 and PT-141 are two cyclic heptapeptide compounds frequently compared in peptide research literature. Both are synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) and both act as melanocortin receptor agonists, but they differ in receptor subtype selectivity, molecular structure, and the research pathways in which each has been investigated. This comparison puts both compounds in analytical and pre-clinical research perspective, with batch-level purity data drawn from HPLC verification performed by Krause Analytical (DEA-registered, ISO/IEC 17025-certified).

Research observations cited in this article are drawn from published pre-clinical and in vitro literature. These compounds are supplied by OPTMZ Peptides strictly for laboratory research use.

What Are Melanotan 2 and PT-141?

Melanotan 2 (MT-2) is a synthetic cyclic heptapeptide analog of α-MSH, developed in the 1980s at the University of Arizona as part of early melanocortin pharmacology research (Hruby et al., 1987, PubMed). It binds to multiple melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R.

PT-141 (bremelanotide) is a metabolite of Melanotan 2, developed as an MC3R/MC4R-selective analog. It retains the core cyclic heptapeptide structure of Melanotan 2 but has been characterized in published research as differing by the replacement of the C-terminal amide with a carboxylic acid, altering its receptor binding profile and eliminating a significant portion of MC1R affinity (Molinoff et al., 2003, PubMed).

Both compounds are supplied by OPTMZ Peptides as research-grade peptides, with each batch independently verified by Krause Analytical. Current batch purity for both compounds is ≥99% by HPLC. Complete batch data — including identity confirmation by mass spectrometry, endotoxin results, heavy metals analysis (ICP-MS), and microbial testing — is published in the OPTMZ COA Vault.

How Do Melanotan 2 and PT-141 Differ Structurally?

The two compounds share a common structural origin but diverge in one functionally significant position.

Both compounds preserve the core Nle⁴-DPhe⁷ substitution that confers resistance to enzymatic degradation compared to native α-MSH. The key differentiator is the C-terminal modification in PT-141, which researchers have associated with altered receptor selectivity profiles (King et al., 2007, PubMed).

What Melanocortin Receptors Does Each Compound Target?

The human melanocortin receptor family consists of five subtypes (MC1R–MC5R), each coupled to Gs proteins and cAMP signaling, and each associated with distinct tissue distributions and research pathways.

Melanotan 2 — Broad-Spectrum Receptor Activity

In vitro binding studies have reported Melanotan 2 as a non-selective melanocortin receptor agonist, with measurable activity at MC1R, MC3R, MC4R, and MC5R (Hruby et al., 1995, PubMed). The MC1R activity is most often cited in pigmentation research — MC1R is primarily expressed on melanocytes and mediates signaling pathways involved in melanin synthesis.

PT-141 — MC3R/MC4R-Selective Profile

Pre-clinical pharmacology studies have characterized PT-141 as displaying a shifted receptor binding profile compared to its parent compound, with retained activity at MC3R and MC4R and reduced MC1R affinity (Rosen et al., 2004, PubMed). MC4R is highly expressed in the central nervous system and has been studied in the context of neuroendocrine signaling pathway research. MC3R displays a broader tissue distribution including CNS, placental, and gastrointestinal expression.

What Research Pathways Have Each Compound Been Studied In?

The structural differences between the two compounds have historically directed them into distinct research domains.

Melanotan 2 Research Areas

Published pre-clinical literature examining Melanotan 2 has investigated:

• Melanogenesis pathway research — in vitro studies of MC1R activation and downstream tyrosinase activity in cultured melanocyte models (Dorr et al., 1996, PubMed)
• Melanocortin receptor cyclase coupling — cAMP signaling assays following receptor activation across cell line models
• Receptor-ligand interaction mechanisms — binding kinetics studies in recombinant receptor expression systems

PT-141 Research Areas

Published pre-clinical literature examining PT-141 has investigated:

• MC4R-mediated CNS signaling research — animal model studies of central MC4R activation and downstream neurochemical signaling (Pfaus et al., 2004, PubMed)
• Neuroendocrine pathway interactions — rodent model studies examining hypothalamic signaling cascades following MC4R agonism
• Receptor pharmacology characterization — comparative binding affinity and functional activation studies relative to α-MSH and other melanocortin ligands

A comprehensive review of melanocortin receptor pharmacology in both compounds is available in King et al. (2007, PubMed).

Why Analytical Verification Matters for Both Compounds

Melanotan 2 and PT-141 are both cyclic heptapeptides, which creates specific analytical challenges. Cyclic peptides require careful synthesis verification because incomplete cyclization can produce linear impurities that share close mass but differ significantly in functional behavior. Because the two compounds differ by a single functional group at the C-terminus, analytical methods must be capable of distinguishing them with high confidence.

HPLC Purity Verification

Reverse-phase high-performance liquid chromatography (HPLC) is the industry-standard method for determining peptide purity. For cyclic heptapeptides in this class, HPLC separates the target compound from synthesis-related impurities including linear precursors, diastereomers, and truncated sequences. OPTMZ Peptides applies a minimum purity threshold of 98% for every batch, with rejected batches never entering inventory. Current batches for both Melanotan 2 and PT-141 have tested ≥99% pure by HPLC.

Mass Spectrometry Identity Confirmation

Mass spectrometry (MS) provides molecular weight confirmation — a critical test for differentiating Melanotan 2 (1024.18 g/mol) from PT-141 (1025.2 g/mol). The ~1 Da difference arising from the amide-to-carboxylic-acid substitution is within the resolution of standard peptide mass spectrometry but requires careful method application. Every OPTMZ batch is MS-identity-confirmed by Krause Analytical in Austin, TX.

Additional Testing

Every batch of both compounds is also tested for:

• Endotoxin (LAL assay)
• Heavy metals (ICP-MS)
• Microbial contamination
• pH stability
• Visual inspection of the lyophilized powder

Batch-level Certificates of Analysis are published at the OPTMZ COA Vault, searchable by the batch number printed on the vial label.

Melanotan 2 vs PT-141 — Summary Comparison

Which Compound Is Right for a Given Research Application?

The selection of Melanotan 2 versus PT-141 in a research context depends on the receptor pathway under investigation. Research examining broad melanocortin pharmacology, MC1R-mediated pathways, or multi-subtype signaling comparisons has historically used Melanotan 2. Research specifically examining MC3R/MC4R-mediated signaling pathways, with an interest in minimizing MC1R cross-reactivity, has typically used PT-141.

For any comparative in vitro or pre-clinical study, verification of both compounds is essential. Because the two peptides differ by a single functional group, confirmation of compound identity via mass spectrometry — in addition to HPLC purity — is a standard requirement. OPTMZ provides both tests on every batch, with data published in the Lab Results archive.

For a full walkthrough of the testing panel applied to every OPTMZ batch, see How We Test.

Citations

1. Hruby, V.J., Lu, D., Sharma, S.D., et al. (1987). Cyclic lactam α-melanotropin analogues. Journal of Medicinal Chemistry, 30(11), 2126–2130. PubMed
2. Hruby, V.J., Lu, D., Sharma, S.D., et al. (1995). Cyclic lactam analogues of Ac-Nle⁴-cyclo[Asp⁵,D-Phe⁷,Lys¹⁰]α-melanocyte-stimulating hormone-(4-10)-NH₂. Journal of Medicinal Chemistry, 38(18), 3454–3461. PubMed
3. Dorr, R.T., Lines, R., Levine, N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784. PubMed
4. Molinoff, P.B., Shadiack, A.M., Earle, D., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102. PubMed
5. Rosen, R.C., Diamond, L.E., Earle, D.C., et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141. International Journal of Impotence Research, 16(2), 135–142. PubMed
6. Pfaus, J.G., Shadiack, A., Van Soest, T., et al. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 101(27), 10201–10204. PubMed
7. King, S.H., Mayorov, A.V., Balse-Srinivasan, P., et al. (2007). Melanocortin receptors, melanotropic peptides and penile erection. Current Topics in Medicinal Chemistry, 7(11), 1098–1106. PubMed

Dr. Leonard Haberman is Chief Science Officer at OPTMZ Peptides, overseeing analytical quality assurance and third-party laboratory partnerships with a focus on HPLC-based purity verification and research-grade peptide compound validation. All research peptides sold by OPTMZ Peptides are intended strictly for laboratory research use only.